ҽҩ֪ʶ
ҽҩ֪ʶ
ҽҩ֪ʶ
ҽҩ֪ʶ
  • ٰ߰Ƽ԰Ѫ

    ߰palbociclibIBRANCE˾ģҩƷIBRANCE£ۣĿǰйСһøƼΪдƼ(ER)-ԡ˱Ƥ2(HER2)-鰩Ůơʾ߰ҩȣʹٰ޽չӳһϣٰߵϣо֣߰ƶٰЧƼ԰ѪAMLоɹ˹־Cancer CellϡϤ

  • ٰʹ߰ŮԻһ

    FDA׼ٰҩIbrance Ʒ£ͨ߰ضڷƣƼ壨HRԡ˱Ƥ2HER2ԵڻתٰԻߡFDAʾ֤Իʹ߰İȫͻŮԻһ¡øƼ߰2015״λ׼뷼㻯øƼʹãΪڸŮĵһֻڼصƷҩṩԵӽ¼ʵݵķΪһ֧֤߰ڷƷ

  • ALTA-1Lоһ߲ЧʤᣡЩ

    2019ŷڿѧѧ-ᣨEMSO-ASIAϣѧRoss CamidgeڴϱALTA-1Lٴоݣоٴ͹Բ׿ԽЧоУ137߽ܲƣ138߽ܿơҪյǶίԱᣨBIRC޽չʣPFSҪյڣOS͹ۻʣORR­ORR­PFSȫԺԡBIRCIJλ޽չڣmPFSΪ 24.0£mPFSΪ11.0¡оPFSУ

  • һALKԻѡ񲼼ỹǰãļ۸

    ֪벼ᶼALKԻߵҩôһƾѡ񲼼ᣬǰأҩЧ˵еALEXоУоİλPFS34.8£ȺЧͻս57%ͨALTA-1LALEXоݽԱȿ֪1ĻǰԽܹƣĻǵijΣǰܹƲûӰ첼ߴ棬ĻûнܹƣǶȿͰЧӽ

  • ˷ļ̷ҩЧΣҩУ

    һձչĵۡIIٴоĻҪǰᡢҩĻߣҲһЩδϵͳƵķΰߡ7첼ʹüΪÿ90ˣȻȵÿ180ˡĻ47ʹð֮ҩ֮ǰʹÿᣩֹоݷʱλʱ12.4£47е14ʹòᡣͼ1 ȰҩҩʹòЧͼʾڰҩĻУٴʹòЧΪ34%

  • ҩLumoxitiëϸѪŷ׼ЧΣ

    ŷҩ׼ݿݣҩLumoxitimoxetumomab pasudotoxջŷίԱᣨEC׼ҩһֿCD-22߶أƼѽܹ2ϵͳƷʺ[PNA]ʧܵĸԻëϸѪHCL˻ߡ20189ѻӦ֢Lumoxitiŷ˵׼ڹؼIIIٴоStudy 1053ݡоһۡо802ַĸԻHCL˻пչLumoxitiҩƵЧͰȫ

  • йѪҩἪƬFLT3ͻ伱ϵѪЧôЩã

    գйҩƷල֣NMPAѸ׼ʼ̹®ӢƷXospata® ͨἪƬͳΪᣬƲþ֤ļⷽ⵽ЯFMSҰἤø3FLT3ͻĸԣԣҩϵѪAML˻ߡϵѪAMLһӰѪҺ͹䷢ӡAMLdzİѪ֮һݹƣĿǰйÿԼ8ϻаѪ˴й׼IIIADMIRALоĽýѷڡ

  • ʲôʱУϼι

    ΰȫ֢ԭλǶཡвĶ֮һзΰУСϸΰ(NSCLC)Լռ85%ALKԵķСϸΰ3%-5%֮䡣ƵĽչALKNSCLCߵԤǰALKƼһޣһʱᷢҩij֣ıⲿֻߵˣԿ˷֪ALKƼҩͻ䣬Ѫͨ͸ԸߣԷϵͳתƵķСϸΰܷӺܺõЧҩFDA׼ǻ(B7461001;NCT01970865)о

  • Ӧ֢ƣҩϼУ۸Ƕ٣

    һ͵ġתġǿЧСALKROS1Ƽ֪ALKҩͻ䶼ǿҵãΪALKƼӦ֢1ALKںԻߵһУõҩĿǰᡢɫᡢͲᣬIƼƼǰᣬЧá2ALK-TKIҩһչΪ߱ƷֻһALKͻİҩְҩĿALKͻĶɫᣬᣬᡣ

  • ALKתԷСϸΰЧתƻ­ڲ建Ϊ82%

    20201228գFDAᣨLorlatinibLorbrenaӦ֢ʸһALKתԷСϸΰߡΪALKԷСϸΰҩҩͷͷĶԱоȫ˿ᣬڰתƲʡ޽չڵȶ棬ȫˢˡʯеЧ¼­ڲ建82%ȫ71%˴εʸ裬ڹؼĢCROWNڽڸУо߶ԱͿҩALKתԷСϸΰߵЧ

  • ϼҩļ۸

    ALKͻֱΪΰġʯͻ䣬ҩһALKƼƵ建ʿԴﵽ50%PROFILE 1005о~61%Study 1001о᱾ԲѣʹѾתƵĻ߻档20201228գFDAᣨLorlatinibLorbrenaӦ֢ʸһALKתԷСϸΰߡΪALKԷСϸΰҩҩͷͷĶԱоȫˡᣬڰתƲʡ޽չڵȶ棬ȫˢˡʯ

  • ϼҩУ

    ΰȫҹʺͷʾһĶNSCLCԼռ80%-85%ܰøALKNSCLCҪ°֮һNSCLCУ5%-7%ĻߴALKͻ䡣ALKںNSCLCҪưе㣬Сʯͻ䡱֮ơFDA׼һALK-TKIĿǰȫѾ׼ALK-TKIsALK-TKIᡢᡢᡢɳᣬALK-TKIᡣһALKNSCLCsNDAFDAڴջ׼˽⣬᲻ֻӡԭҩ棬ϼ

  • LorlatinibһALKԷСϸΰЧô۸

    Lorlatinibǻ𿪷һ͡桢ǿЧСALKROS1ƼALKROS1ԼTYK1FERFPSTRKATRKBTRKCFAKFAK2ACKƻԡ201811£ҩFDA׼ƽܿᣨԼһALKƼԽչܰΪһALKƼƺԽչALKתNSCLCߡLorlatinibһALKNSCLCsNDAǻCROWNооһűǩġIIIоּڱȽLorlatinibͿδƵALKNSCLCһƵ

  • ³ᣫƸ/ܰϸѪߵЧ͸ã

    оּ³ƷжUblituximab, һֿCD20¡壩Ƹ/ܰϸѪߵЧ档һĵ3оļ18Я17pȱʧ11qȱʧTP53ͻĸ/ܰϸѪߣ1:1飬³ᵥƻ³ơҪյܻʡ201526-20161219գ224λߣ126λо飺 64ˡ³ᵥҩ 62ˡλ41.6£

  • άο/άпйʱ䣿

    άпѱFDA׼öҩҸεȾɫ17pȱʧܰϸѪҲFDA׼׸Bϸܰ-2(B-cell lymphoma 2,BCL-2)СƼҩ2020112գάAbbVieذҩάпˣvenetoclaxйҩҩƷģCDE걨У3CDEţJXHS2000002/3/4ֹĿǰάпˣvenetoclaxδʽйСһΪCLL14Ĺʶġűǩо432ߣ1:1顣оʹά

  • ˹ҩй걨Ум

    ˹أapremilastһ͵ĿڷСø4PDE4Ƽͨ໬ĤϸͷӣTNF-áòƷɰʱʩ󱦣BMS»˾з20198Ըߴ134Ԫչ˰˹ȫȨ档˹ѱڰ߿ммؽסؿǻӦ֢ߡ23գɰ»ͬύİ˹Ƭҩѻǰ˹мؽ׺мӦ֢Ѿһٴ辳ҩ

  • ΰحLibtayoӳ

    2021213գҶһΪEMPOWER-Lung 1IIIʾڷСϸΰNSCLCĻߣPD-L1߱Ļߣ벬໯ȣLibtayoΪһƿӳڣOS޽չڣPFSġűǩȫIIIٴУоԱʼ鵥ҩLibtayoͲ˫ػƶPD-L150%NSCLCߵһЧƣITTȺn=710563PD-L150%Ļߺ56PD-L150%ĻߡоҪյOSPFSҪյ͹ۻʣORR

  • άοЧάοҩУʲôʱ

    άοƬ (Venetoclax) VENCLEXTAΪάпˡȫ׿BCL-2Ƽҩʱάп˿ЧBCL-2ĹܣҩӰϸҩԣPFS(޽չ)ӳʱ䡣1.άп˶17PȱʧܰͰЧʸߴ71%20%ȫ⣬ʸߴ84%ҸñȽᡣ2.Venetoclax(άп)ǰýBCL-2MCL-1BCL-XL׼⡣ϸֻBCL-2ܸߣûMCL-1BCL-XLdzЧĸʻӡϸͬʱ߱BCL-2MCL-1

  • ѪҩάпˣvenetoclaxЧԣάпηҩô

    άпˣvenetoclaxάAbbVie˾ʿϣRoche˾з׿Bϸܰ2BCL-2ѡҩ2016׼СƣܰϸѪ(CLL)Сܰϸܰ(SLL)˼ϵѪ(AML)άпˣvenetoclax һBCL-2ƼBCL-2һְϸĵף֢ڵBCL-2׻ֹϸBCL-2ƼʹBCL-2ʧȥԣӶʹڵİϸάпˣvenetoclax ܰϸѪ96%Ļȫ

  • ƹתƻЧôϼҩι

    תǺܶڶ޷ֵļת飬رٰǰٰΰٰǰٰйתƵķʸߴ70%ϣΰݱһеĸߴ85%ƺԹתЧѡһIIоУÿƶʵʾ184Ըΰǰٰѳתƻߵļʷֱɴ76%71%58%ɫٰͷСϸΰתƵļʷֱΪ45%45%40%ڹתУʹЧҩ󣬿Կѡ񿨲ᡣݺÿҽѧ˽⵽

共有184页首页上一页123456789下一页尾页
客服中心
联系方式
400-001-9763
- ѯ
ɨάѯ